KDR and central nervous system cancer: Kessler et al. detected VEGFR2 immunopositivity in 19% of the specimens and showed increased aggressiveness and shorter survival associated with VEGFR2 overexpression in glioma cells, by hampering antiangiogenesis and inducing a proinvasive response to bevacizumab21.